Table 3.

Comparison of the Effect of Extranasal Stimulation and Intranasal Stimulation on Change from Baseline in Schirmer Scores Between Subgroups Defined by Sjögren Syndrome Medication Use and Baseline Schirmer Score

Change from Baseline in Schirmer Test Score	Extranasal Stimulation	Intranasal Stimulation
On Sjögren Syndrome Medication (n=52 eyes): Mean (SE) mm/5 min	1.5 (1.1)	14.3 (1.9)
Not on Sjögren Syndrome Medication (n=18 eyes): Mean (SE) mm/5 min	−1.1 (0.8)	11.1 (2.5)
Difference (95% CI) mm/5 min	2.6 (−0.05, 5.2)	3.2 (−2.9, 9.4)
P-value	0.054	0.30
Baseline Schirmer <5 mm/5 min (n=17 eyes): Mean (SE) mm/5 min	2.9 (1.3)	14.8 (2.8)
Baseline Schirmer ≥5 mm/5 min (n=53 eyes): Mean (SE) mm/5 min	−0.5 (1.0)	12.6 (1.8)
Difference (95% CI) mm/5 min	3.4 (0.1, 6.6)	2.2 (−4.4, 8.8)
P-value	0.04	0.51